## ADVANCE CARE PLANNING IN REHABILITATION: AN IMPLEMENTATION STUDY

Krystal SONG, MBBS, FAFRM (RACP)<sup>1-3</sup>, Bhasker AMATYA, DMedSCI, MD, MPH<sup>1-3</sup> and Fary KHAN, MBBS, MD, FAFRM (RACP)<sup>1-3</sup>

From the <sup>1</sup>Department of Rehabilitation Medicine and <sup>2</sup>Australian Rehabilitation Research Centre, Royal Melbourne Hospital (RMH), Victoria, and <sup>3</sup>Department of Medicine (RMH), University of Melbourne, Melbourne, Australia

**Objective:** To identify implementation and process issues that influence the implementation of an advance care planning (ACP) programme in rehabilitation settings.

Methods: An ACP programme was established in an inpatient tertiary rehabilitation setting in Victoria, Australia. Rehabilitation patients with chronic illnesses were recruited and the Reach, Effectiveness, Adoption, Implementation and Maintenance (RE-AIM) framework used. Pre-implementation measures included: patient medical record audit of ACP discussions; and barriers and facilitators analyses. Implementation interventions were staff group educational sessions and clinical process changes. Further medical record audit was carried out to review the number of ACP conversations performed and re-evaluate ACP barriers.

**Results:** A total of 180 consecutive inpatients were recruited for pre- (n=90) and post- (n=90) implementation groups. The majority of the pre-implementation cohort were female (51%), mean age 64.2 years (standard deviation 16.4 years) and had low rates of ACP discussions (n=9, 10%). Major ACP barriers included: lack of staff education programme, and insufficient knowledge to conduct ACP. There was a significant increase in ACP conversations performed (n=21, 23.3%) between both groups; however, staff reported limited time and skills to perform discussions.

*Conclusion:* This ACP programme is feasible, but needs robust process evaluation and longer term follow-up to assess the impact of outcomes in public hospital settings on care quality.

*Key words:* advance care planning; end-of-life care; quality improvement; rehabilitation.

Accepted April 16, 2018; Epub ahead of print Jun 12, 2018

J Rehabil Med 2018; 50: 652-660

Correspondence address: Krystal Song, Department of Rehabilitation Medicine, Royal Melbourne Hospital, Royal Park Campus, 34–54 Poplar Road, Parkville, Victoria, Australia. E-mail: krystal.song@mh.org.au

The Australian population aged over 65 years is growing, and is predicted to exceed 20% of the total population by 2033 (1). In Victoria (the second largest state in Australia), approximately 36,000 people die each year and this number will double in the next 25 years. Approximately half of these people will die following chronic life-limiting illnesses, such as

## LAY ABSTRACT

Advance care planning (ACP) is the process of planning for future healthcare and life-prolonging treatment preferences to guide clinical decision-making when one is unable to communicate decisions due to lack of capacity. We evaluated the effectiveness of an ACP programme in an inpatient rehabilitation setting in Australia with patients with chronic illnesses. This programme identified barriers and enablers, with implementation of ACP strategies in this setting, resulting in an increase in ACP conversations between rehabilitation staff and patients. The programme is feasible, but needs longer-term follow-up to assess the impact of outcomes on improved care quality.

heart disease, chronic obstructive pulmonary disease (COPD), cancer, stroke or progressive neurological illnesses (1). Patients with chronic illnesses often experience disabilities, such as fatigue, difficulties with mobility and self-care, and psychological problems (such as depression and anxiety). There are significant implications of these disabilities on functional capacity (and caregivers), with role reversal within families. Chronic illnesses also account for more frequent hospitalizations, longer length of hospital stay, impaired quality of life (QoL) and high financial burden (2).

Advance care planning (ACP) has been identified as an effective tool for future care planning in those with chronic illnesses. It allows patients to communicate their values, beliefs, goals of care, and future treatment preferences in the event that they are unable to do so (3). ACP can take many forms, and in the state of Victoria, Australia, this includes medical enduring power of attorney (MEPOA), statement of choices, refusal of treatment certificate and/or advance directive (AD) (4). ACP enables patient autonomy, shared decision-making processes, and helps ensure that patients receive end-of-life (EOL) care consistent with their life values and goals. ACP also enhances patients' QoL, encourages better management and coordination of existing resources, improves service provision and ultimately, provides patient-centred care, with reduced stress on families and carers (3-5).

Despite the known benefits of ACP, research has shown it has limited uptake in Australia and internationally (4–6). AD completion rates remain low and range from 5-15% in the general population (7). Patients with chronic illnesses often benefit from palliative care

services to improve their QoL; however, these services are limited by poor access, and patients are usually referred late in their illness trajectory. Most patients in later stages of their disease course also lose their cognitive capacity, which limits their ability to participate in EOL decision-making (8, 9). The "neuropalliative rehabilitation" model of care offers a comprehensive and integrated approach to delivery of ACP (10). This model highlights the key supportive role of the rehabilitation multidisciplinary team in discussing ACP with patients, given the expertise of different clinicians in being able to translate wishes and values of patients, aligned with their goals, into a clinical treatment plan.

In rehabilitation settings internationally and in Australia, it is clear that little is known about how ACP processes occur and evidence for the efficacy of ACP interventions (11, 12). To develop, implement and evaluate complex health interventions, such as ACP, requires careful consideration, not only of the outcomes, but also of the processes involved (13). Process evaluation improves understanding of underlying mechanisms related to patients, clinicians, context and intervention delivery, which may have an impact on programme results and sustainability in practice (14). ACP contains multiple interacting components, including heterogeneity of patients, multimodal ACP components, ethical and legal considerations, as well as cultural and religious factors that may lead to a range of possible outcomes. Lack of impact may thus reflect programme implementation failure, rather than ineffectiveness of the programme (15).

The Reach, Effectiveness, Adoption, Implementation and Maintenance (RE-AIM) implementation framework addresses important aspects in process evaluation to help translate research into evidence-based practice, and helps plan programmes to be realistic to adopt in relevant clinical settings (16). Given that most rehabilitation patients have chronic illnesses that require ACP discussions, and rehabilitation settings offer the best opportunities to deliver ACP, this study aimed to use qualitative and quantitative analyses, in the context of the RE-AIM framework (16), to evaluate the feasibility and effectiveness of a structured ACP programme in an inpatient rehabilitation setting in a tertiary hospital in Victoria, Australia.

#### METHODS

## Participants and setting

Patients were recruited from the inpatient rehabilitation unit of the Royal Melbourne Hospital (RMH), a major tertiary hospital in Victoria, Australia from March to October 2017. This quality improvement initiative was approved by the RMH Human Research and Ethics Committee (HREC 2014.033). The 35-bed tertiary rehabilitation unit receives rehabilitation referrals from the acute medical and surgical wards. A total of 90 patients were identified from the inpatient rehabilitation ward, and consecutively recruited for each pre- and post-implementation group. The inclusion criteria were based on state government guidelines (2): (*i*) patients with confirmed diagnosis of a chronic life-limiting illness (e.g. stroke, neurodegenerative disorder, heart failure, brain tumours), and/or those with multiple co-morbidities; (*ii*) age 18 years and above; (*iii*) willing to participate and able to give informed consent; and (*iv*) medically stable. Exclusion criteria included those with: (*i*) severe cognitive impairment; and (*ii*) severe psychiatric illness that required hospitalization in the past year.

For the written survey and staff focus groups, all 42 members of rehabilitation department staff registered in the department were invited to participate by email and by post. Of those who responded, 5 were selected randomly from each discipline (medical, nursing, allied health) in order to obtain representation from each group.

#### Procedure

Three phases of implementation were carried out in this ACP programme (Fig. 1). Intervention activities in each phase included:

#### 1) Pre-implementation phase (March – June 2017)

- *Medical record audit.* A medical record audit of consecutively admitted rehabilitation inpatients (n=90) was performed from March to May 2017. Information collected included patient-related variables (demographic, medical information), presence of ACP discussions, MEPOA nomination, and AD documentation. This information helps identify the status of ACP conversations performed between rehabilitation staff and patients, and the presence of documentation in the inpatient ward.
- ACP barriers and facilitators written survey. A literature search
  of barriers and facilitators to ACP was initially conducted to
  identify relevant studies through the PubMed database and a
  snowballing review of reference lists of relevant studies. Data
  were extracted and compiled by 2 authors (KS, FK). Any discrepant views on inclusions and exclusions of the articles were
  resolved by the third author (BA) and group consensus. Based
  on the findings from the literature review, a written survey tool
  (see Appendix SI<sup>1</sup>) was developed to capture perceived personal

<sup>1</sup>http://www.medicaljournals.se/jrm/content/?doi=10.2340/16501977-2356

Pre-implementation




Fig. 1. Implementation phases. ACP: advance care planning; MEPOA: medical enduring power of attorney; AD: advance directive.

Journal of Rehabilitation Medicine

(staff) and systemic barriers and facilitators to ACP implementation. This tool was distributed to all rehabilitation staff (n=42) in the unit to complete in May 2017 and return anonymously in a sealed envelope to the principal investigator (KS).

 Focus groups. Three focus groups, each of 1 h duration, were held with 5 medical, 5 nursing and 5 allied health staff, respectively, to assess their experiences with ACP discussions with patients and identify barriers and facilitators to ACP implementation. These focus group discussions help identify gaps in clinical practice and strategies, which could be used in implementation phase of the ACP programme.

Staff were invited by email to participate in the study. Once they had consented, they were recruited for the focus groups. The primary researcher (KS) conducted ACP discussions involving face-to-face interviews, using open-ended and closed questions to determine staff experience, attitudes and beliefs to ACP implementation. These focus groups were performed in May 2017 in a private meeting room in the rehabilitation ward. These interviews were audiotaped and transcribed by the primary researcher (KS) and information stored in a locked office at the RMH.

#### 2) Implementation phase (July to August 2017)

• ACP educational sessions were delivered to rehabilitation staff by a rehabilitation consultant and ACP facilitator, both with expertise in ACP education. Three educational sessions, each 60 min duration, were performed separately with each discipline (including medical, nursing and allied health) over a period of 3 weeks from July to August 2017. An additional combined multidisciplinary forum (including medical, nursing and allied health staff) of approximately 1.5 h duration was held separately during this period.

Each educational session involved the provision of reading materials prior to the session. During the session, the results of the pre-implementation medical record audit were initially presented to allow staff to appraise the current status of ACP discussions with patients and documentation. Furthermore, a didactic teaching session was conducted, using a standardized presentation to demonstrate and describe the key principles of ACP, how to approach and facilitate ACP conversations

with patients, documentation forms including AD, and helpful communication skills using ACP videos. In addition, patient and clinician educational resources were provided.

• Implementation of Clinical Process Changes in the rehabilitation ward setting, which included provision of ACP information brochures to patients, incorporation of ACP into multidisciplinary meeting checklists, provision of ACP documents (i.e. MEPOA nomination, Refusal of Treatment Certificate and AD forms) on the ward for patients, and embedding of ACP discussion forms into patient medical records for documentation of ACP discussions by the rehabilitation team.

3) Post-implementation phase (September to October 2017)

- *Medical record audit.* A medical record audit was further performed of consecutively admitted rehabilitation patients (*n*=90) to analyse post-implementation status of ACP discussions and documentation.
- *Focus groups*. Three focus groups, of 1 h duration each, were held with 5 medical, 5 nursing and 5 allied health staff, respectively, to further assess their experiences with ACP implementation interventions. These focus

groups were held in October 2017, using a private meeting room in the rehabilitation ward. Barriers and facilitators to ACP implementation were explored using open-ended and closed questions. These interviews were digitally recorded and transcribed verbatim by the principal investigator (KS).

#### Programme logic

The development, implementation and evaluation of an ACP programme require process evaluation to allow the identification of implementation issues, and contextual factors that may influence outcomes. This allows the adoption of strategies to help translate clinical research findings into routine care. Process evaluation involves the use of both quantitative and qualitative research methods in combination (17, 18), which provide a better understanding of the effectiveness of rehabilitation programmes involving ACP. The use of several indicators that can be linked to programme and service inputs, and programme and service outputs informs a good process evaluation plan. Examples of service inputs include participants (e.g. number, demographic background), setting where services are provided (e.g. inpatient, outpatient), quality of services, and intervention delivery (e.g. type, fidelity to plan). Examples of service outputs include service completion and intervention (e.g. satisfaction) (19). Each of the process indicators maps directly back onto a programme logic model and key process evaluation questions.

Fig. 2 outlines the programme logic for ACP programme, including the programme inputs, activities and potential impacts. The programme logic was developed and reviewed at different times in the programme cycle: before the programme started, during implementation and as part of the programme evaluation.

#### Process evaluation tool and outcome measures

#### 1) Reach, Effectiveness, Adoption, Implementation and Maintenance framework

 The RE-AIM framework informs the evaluation of implementation and delivery of our ACP programme as it addresses key areas of process evaluation including: sampling, recruitment, reach, acceptability and quality of the intervention, barriers




Fig. 2. Programme logic diagram. ACP: advance care planning; MEPOA: medical enduring power of attorney; AD: advance directive.

and facilitators, and contextual influences (13, 16). This framework also highlights the relative strengths and weaknesses of the programme by evaluating 5 key domains (Fig. 3). Key evaluation questions for which data were collected in this study are summarized in Table I.

## 2) Outcome measures

Journal of Rehabilitation Medicine

· Pre-implementation phase

Medical record audit data collected included: patientrelated variables (demographic, medical information), level of cognitive impairment (documented in clinical admission notes), presence of ACP discussions from progress notes, presence of MEPOA nomination, and AD documentation on electronic medical record system.

Information regarding ACP barriers and facilitators, as well as staff experiences with ACP were collected through a combination of qualitative staff survey feedback forms and focus group discussions.

Post-implementation phase •

Medical record audit data collected included: patient-related variables (demographic, medical information, level of cognitive impairment, etc.), presence of ACP discussions from




Fig. 3. Five steps of programme evaluation using the Reach, Effectiveness, Adoption, Implementation, Maintenance (RE-AIM) framework (14).

progress notes, presence of MEPOA nomination, and AD documentation on electronic medical record system.

ACP barriers and facilitators were explored through staff focus group discussions.

#### Statistical analysis

Descriptive summary statistics were generated for pre- and postimplementation patient medical record audit results. For the staff

Table I. Process evaluation questions related to Reach, Effectiveness, Adoption, Implementation, Maintenance (RE-AIM) domains and associated data collection tools

RE-AIM domains	s Data collected	Key evaluation questions	Data collection tools
Reach	Absolute number, proportion and representativeness of individuals who are willing to participate in a given initiative	How is target population reached with intervention?	Description of recruitment methods
		How well did intervention reach all those potentially eligible?	Screening and recruitment data
Effectiveness	Impact of intervention on important outcomes and intervention details	Did the programme achieve its intended objectives?	Medical record audit (ACP discussion/ MEPOA nomination/AD completion)
		What intervention activities took place?	ACP educational workshop, clinical process changes
		Who conducted intervention activities?	Descriptive data in study design
Adoption	Absolute number, proportion representativeness of settings and staff who are willing to initiate a programme	What were the attitudes and beliefs of staff towards intervention?	Qualitative barriers and facilitators feedback survey tool and focus groups
	Adherence and attitudes of staff to intervention	Was intervention adopted by treating clinical staff?	Medical record audit (ACP discussion documentation)
	Participant recruitment, adherence levels and drop outs	Was intervention adopted by participants? What were the attitudes and beliefs of participants towards intervention?	Quantitative outcome measures (ACP conversation documentation forms, MEPOA nomination, AD completion rates)
Implementation	Staff attitudes and fidelity to various elements of intervention's protocol (consistency of delivery, time and cost of intervention, adaptations made during delivery)	To what extent was intervention implemented as planned?	Number of educational sessions to different disciplines and multidisciplinary forum
		Was the programme relevant (i.e. goal directed and useful)?	Audit of ACP discussion forms and medical clinical progress notes
		What were the barriers and enablers to programme delivery?	Qualitative barriers and enablers feedback survey form evaluating rehabilitation staff perspectives
		Were there adaptations made during programme delivery?	Clinical process changes
		What were the areas of the programme that need improvement?	Clinical process changes
		What were the treatment costs?	Calculation of direct costs for provision of inpatient rehabilitation programme
		What inputs/resources were allocated for programme implementation?	Hospital inpatient rehabilitation programme and staff resources; infrastructure
		How did external factors influence programme delivery?	Interview with rehabilitation staff key managers including medical, nursing and allied health staff
		Was the structure or logic of the programme appropriate?	Refer to Fig. 2
Maintenance	Extent to which programme or policy become part of routine organisational practices and policies	Is long-term implementation feasible?	Interviews with key managers including medical, nursing and allied health staff
		Was the data used to change practice?	Multidisciplinary ACP forums
		What were the long-term benefits for participants	To be evaluated in future longer term studies

Journal of Rehabilitation Medicine

ACP: advance care planning: MEPOA: medical enduring power of attorney: AD: advance directive.

ACP survey and focus group discussions, qualitative analysis of rehabilitation staff barriers and facilitators to ACP implementation was performed and described descriptively. Specifically, interview transcripts from focus group discussions in both pre- and post-implementation phases were analysed, coded and interpreted using thematic analyses. Thematic analysis is based on an inductive process that allowed for themes to emerge, and to enable management of large amounts of qualitative data in a credible and robust manner. Transcripts were individually read, "open" coded and emergent thematic features were collectively discussed, categorized and summarized under each topic domain by 2 investigators (KS, FK) until agreement was reached.

## RESULTS

A total of 180 patients were enrolled in this study, with 90 patients in each pre- and post-implementation group. The socio-demographic and disease characteristics of both patient cohorts are demonstrated in Table II. Both groups were well-matched for demographic and clinical characteristics, with no drop-outs recorded.

## Participant characteristics

## 1) Pre-implementation group

The mean age of participants in this group was 64.2 (standard deviation (SD)=16.4) years, with 51.1% female. The common diagnoses in this group were: orthopaedic (n=42, 46.7%) and stroke (n=17, 18.9%). Only 9 patients (10%) had documented ACP conversations. Furthermore, only 7 patients (7.8%) had a MEPOA; and AD was completed in only 3 patients (3%) (Table II).

## 2) Post-implementation group

Following implementation phase interventions, the post-implementation audit results demonstrated mean age of participants was 66.4 (SD 15.9) years, with 41% being female. Similar to the pre-implementation group, the most common diagnoses on admission were: stroke (n=25, 27.8%) and orthopaedic (n=24, 26.7%).

There was an increase in ACP conversations post-implementation, with 23.3% (n=21) of patients having had documented ACP discussions with rehabilitation staff. There were no significant increases in MEPOA nomination and AD completion rates (Table II). The majority of ACP discussions occurred in males (n=13, 62%), predominantly in those over the age of 60 years (n=17, 82%), and in those with stroke (n=12, 57.1%).

### Interventions used

Different interventions used in the 3 implementation phases are demonstrated in Fig.1. The results of the pre- and post-implementation phase ACP barriers and

#### **Table II.** Pre- and post-implementation audit results (*n* = 180)

Pre-implementationPost-implementationCharacteristics $n$ (%) $cohort (n = 90)$ $n$ (%) $n$ (%)Age, years, mean (SD) [range] $64.2$ (16.4) [25–91] $66.4$ (15.9) [22–93]Sex (female)46 (51.1)41 (45.6)Married/partner35 (38.9)49 (54.4)Living arrangements – family38 (42.2)25 (27.8)Ethnicity (Caucasian)54 (60.0)56 (62.2)Education54 (60.0)56 (62.2)Education56 (95.6)87 (96.7)Postgraduate4 (4.4)3 (3.3)Religion (Christian)4 (4.4)13 (15.5)Employment16 (17.8)13 (15.5)Employed18 (20.0)11 (12.2)Unemployed29 (32.2)29 (32.2)Retired43 (47.8)50 (55.6)Cognition11 (11.1)4 (4.4)Mild impairment10 (11.1)4 (4.4)Moderate impairment5 (5.6)11 (11.1)Diagnosis on admission552 (27.8)Neurological14 (15.6)14 (15.6)Amputation8 (8.9)3 (3.3)Musculoskeletal2 (2.2)4 (4.4)Others7 (7.8)29 (22.2)Comorbidities22Carcer17 (18.9)16 (17.8)Stroke16 (17.8)29 (32.2)Neurological disorders24 (26.7)15 (16.7)Renal9 (10)10 (11.1)Diabetes19 (21.1)14 (45.6)Stroke16 (17.8)2	· · · ·		. ,
Age, years, mean (SD) [range] 64.2 (16.4) [25-91]66.4 (15.9) [22-93]Sex (female)46 (51.1)41 (45.6)Married/partner35 (38.9)49 (54.4)Living arrangements - family38 (42.2)25 (27.8)Ethnicity (Caucasian)54 (60.0)56 (62.2)EducationSecondary/tertiary86 (95.6)87 (96.7)Postgraduate4 (4.4)3 (3.3)Religion (Christian)4 (4.4)4 (4.4)Interpreter required16 (17.8)13 (15.5)Employed18 (20.0)11 (12.2)Unemployed29 (32.2)29 (32.2)Retired43 (47.8)50 (55.6)CognitionIntact75 (83.3)85 (94.4)Mild impairment10 (11.1)4 (4.4)Moderate impairment5 (5.6)1 (1.1)Diagnosis on admissionStroke17 (18.9)24 (26.7)Orthopaedics42 (46.7)25 (27.8)Neurological14 (15.6)14 (15.6)Amputation8 (8.9)3 (3.3)Musculoskeletal2 (2.2)4 (4.4)Others7 (7.8)29 (32.2)Comorbidities20 (21.1)31 (34.3)Cardiovascular33 (36.7)44 (48.9)Pulmonary17 (18.9)16 (17.8)Stroke16 (17.8)29 (32.2)Neurological disorders24 (26.7)Comorbidities19 (21.1)31 (34.3)Hypertension41 (45.6)51 (65.7)Depression25 (27.8)18 (20.0)Anxiety10 (11.1)<	Chaus shawishing	cohort ( <i>n</i> = 90)	cohort $(n = 90)$
Sex (female)46 (51.1)41 (45.6)Married/partner35 (38.9)49 (54.4)Living arrangements - family38 (42.2)25 (27.8)Ethnicity (Caucasian)54 (60.0)56 (62.2)EducationSecondary/tertiary86 (95.6)87 (96.7)Postgraduate4 (4.4)3 (3.3)Religion (Christian)4 (4.4)4 (4.4)Interpreter required16 (17.8)13 (15.5)EmploymentEmployed29 (32.2)29 (32.2)Retired43 (47.8)50 (55.6)CognitionIntact75 (83.3)85 (94.4)Mild impairment10 (11.1)4 (4.4)Moderate impairment5 (5.6)1 (1.1)Diagnosis on admissionStroke17 (18.9)24 (26.7)Orthopaedics42 (46.7)25 (27.8)Neurological14 (15.6)14 (15.6)Amputation8 (8.9)3 (3.3)Musculoskeletal2 (2.2)4 (4.4)Others7 (7.8)29 (22.2)Comorbidities717 (18.9)21 (23.3)Cardiovascular33 (36.7)44 (48.9)Pulmonary17 (18.9)21 (23.3)Cancer17 (18.9)21 (23.3)Cancer17 (18.9)21 (23.3)Cancer19 (21.1)31 (34.3)Hypertension41 (45.6)51 (56.7)Depression25 (27.8)18 (20.0)Anxiety10 (11.1)14 (15.6)Stroke16 (17.8)29 (32.2)Comorbidities19 (21.1)	Characteristics	n (%)	n (%)
Married/partner       35 (38.9)       49 (54.4)         Living arrangements - family       38 (42.2)       25 (27.8)         Ethnicity (Caucasian)       54 (60.0)       56 (62.2)         Education       Secondary/tertiary       86 (95.6)       87 (96.7)         Postgraduate       4 (4.4)       3 (3.3)         Religion (Christian)       4 (4.4)       4 (4.4)         Interpreter required       16 (17.8)       13 (15.5)         Employment       Employed       29 (32.2)       29 (32.2)         Retired       43 (47.8)       50 (55.6)         Cognition       Intact       75 (83.3)       85 (94.4)         Mild impairment       10 (11.1)       4 (4.4)         Moderate impairment       5 (5.6)       11 (12.2)         Diagnosis on admission       Stroke       17 (18.9)       24 (26.7)         Orthopaedics       42 (46.7)       25 (27.8)         Neurological       14 (15.6)       14 (15.6)         Amputation       8 (8.9)       3 (3.3)         Musculoskeletal       2 (2.2)       4 (4.4)         Others       7 (7.8)       29 (32.2)         Comorbidities       13 (15.6)       14 (15.6)         Cardiovascular       33 (36.7)	Age, years, mean (SD) [range]	64.2 (16.4) [25-91]	66.4 (15.9) [22–93]
Living arrangements – family 38 (42.2) 25 (27.8) Ethnicity (Caucasian) 54 (60.0) 56 (62.2) Education Secondary/tertiary 86 (95.6) 87 (96.7) Postgraduate 4 (4.4) 3 (3.3) Religion (Christian) 4 (4.4) 4 (4.4) Interpreter required 16 (17.8) 13 (15.5) Employment Employed 18 (20.0) 11 (12.2) Unemployed 29 (32.2) 29 (32.2) Retired 43 (47.8) 50 (55.6) Cognition Intact 75 (83.3) 85 (94.4) Mild impairment 10 (11.1) 4 (4.4) Moderate impairment 5 (5.6) 1 (1.1) Diagnosis on admission Stroke 17 (18.9) 24 (26.7) Orthopaedics 42 (46.7) 25 (27.8) Neurological 14 (15.6) 14 (15.6) Amputation 8 (8.9) 3 (3.3) Musculoskeletal 2 (2.2) 4 (4.4) Others 7 (7.8) 29 (22.2) Comorbidities Cardiovascular 33 (36.7) 44 (48.9) Pulmonary 17 (18.9) 16 (17.8) Stroke 16 (17.8) 29 (32.2) Neurological disorders 24 (26.7) 15 (16.7) Renal 9 (10) 10 (11.1) Diabetes 19 (21.1) 31 (34.3) Hypertension 41 (45.6) 51 (56.7) Depression 25 (27.8) 18 (20.0) Anxiety 10 (11.1) 14 (15.6) Substance use 14 (15.6) 14 (15.6) Smoker 15 (16.7) 17 (18.9) Other (arthritis, osteoporosis, etc.) 71 (78.9) 65 (72.2) ACP components ACP discussions 9 (10.0) 21 (23.3) MEPOA nomination 7 (7.8) 3 (3.3)	Sex (female)	46 (51.1)	41 (45.6)
Ethnicity (Caucasian)54 (60.0)56 (62.2)EducationSecondary/tertiary86 (95.6)87 (96.7)Postgraduate4 (4.4)3 (3.3)Religion (Christian)4 (4.4)4 (4.4)Interpreter required16 (17.8)13 (15.5)EmploymentEmployed29 (32.2)29 (32.2)Retired43 (47.8)50 (55.6)CognitionIntact75 (83.3)85 (94.4)Mild impairment10 (11.1)4 (4.4)Moderate impairment5 (5.6)1 (1.1)Diagnosis on admissionStroke17 (18.9)24 (26.7)Orthopaedics42 (46.7)25 (27.8)Neurological14 (15.6)14 (15.6)Amputation8 (8.9)3 (3.3)Musculoskeletal2 (2.2)4 (4.4)Others7 (7.8)29 (32.2)Comorbidities24 (26.7)15 (16.7)Cardiovascular33 (36.7)44 (48.9)Pulmonary17 (18.9)11 (12.8)Stroke16 (17.8)29 (32.2)Neurological disorders24 (26.7)15 (16.7)Renal9 (10)10 (11.1)Diabetes19 (21.1)31 (34.3)Hypertension41 (45.6)51 (56.7)Depression25 (27.8)18 (20.0)Anxiety10 (11.1)14 (15.6)Substance use14 (15.6)14 (15.6)Substance use14 (15.6)14 (15.6)Substance use14 (15.6)14 (15.6)Substance use14 (15.6)14	Married/partner	35 (38.9)	49 (54.4)
EducationSecondary/tertiary $86$ (95.6) $87$ (96.7)Postgraduate $4$ (4.4) $3$ (3.3)Religion (Christian) $4$ (4.4) $4$ (4.4)Interpreter required $16$ (17.8) $13$ (15.5)Employment $Employed$ $18$ (20.0) $11$ (12.2)Unemployed $29$ (32.2) $29$ (32.2)Retired $43$ (47.8) $50$ (55.6)Cognition $Intact$ $75$ (83.3) $85$ (94.4)Mild impairment $10$ (11.1) $4$ (4.4)Moderate impairment $5$ (5.6) $11$ (1.1)Diagnosis on admission $Stroke$ $17$ (18.9) $24$ (26.7)Orthopaedics $42$ (46.7) $25$ (27.8)Neurological $14$ (15.6) $14$ (15.6)Amputation $8$ (8.9) $3$ (3.3)Musculoskeletal $2$ (2.2) $4$ (4.4)Others $7$ (7.8) $29$ (22.2)Comorbidities $Cardiovascular$ $33$ (36.7) $44$ (48.9)Pulmonary $17$ (18.9) $16$ (17.8)Stroke $16$ (17.8) $21$ (23.3)Cancer $17$ (18.9) $16$ (17.8)Stroke $16$ (17.8) $29$ (32.2)Neurological disorders $24$ (26.7) $15$ (16.7)Renal $9$ (10) $10$ (11.1)Diabetes $19$ (21.1) $31$ (34.3)Hypertension $41$ (45.6) $51$ (56.7)Depression $25$ (27.8) $18$ (20.0)Anxiety $10$ (11.1) $14$ (15.6)Substance use $14$ (15.6) $14$ (15.6)	Living arrangements – family	38 (42.2)	25 (27.8)
Secondary/tertiary         86 (95.6)         87 (96.7)           Postgraduate         4 (4.4)         3 (3.3)           Religion (Christian)         4 (4.4)         4 (4.4)           Interpreter required         16 (17.8)         13 (15.5)           Employment         Employed         18 (20.0)         11 (12.2)           Unemployed         29 (32.2)         29 (32.2)         Retired           Ag (47.8)         50 (55.6)         Cognition         Intact         75 (83.3)         85 (94.4)           Mild impairment         10 (11.1)         4 (4.4)         Moderate impairment         5 (5.6)         1 (1.1)           Diagnosis on admission         Stroke         17 (18.9)         24 (26.7)         Orthopaedics         42 (46.7)         25 (27.8)           Neurological         14 (15.6)         14 (15.6)         Amputation         8 (8.9)         3 (3.3)           Musculoskeletal         2 (2.2)         4 (4.4)         Others         7 (7.8)         29 (22.2)           Comorbidities         7 (7.8)         29 (22.2)         Comorbidities         20 (22.2)           Cardiovascular         33 (36.7)         44 (48.9)         Pulmonary         17 (18.9)         16 (17.8)           Stroke         16 (17.8) <t< td=""><td>Ethnicity (Caucasian)</td><td>54 (60.0)</td><td>56 (62.2)</td></t<>	Ethnicity (Caucasian)	54 (60.0)	56 (62.2)
Postgraduate         4 (4.4)         3 (3.3)           Religion (Christian)         4 (4.4)         4 (4.4)           Interpreter required         16 (17.8)         13 (15.5)           Employment         Employed         18 (20.0)         11 (12.2)           Unemployed         29 (32.2)         29 (32.2)         Retired           Advantable         29 (32.2)         29 (32.2)         Retired           Cognition         Intact         75 (83.3)         85 (94.4)           Mild impairment         10 (11.1)         4 (4.4)           Moderate impairment         5 (5.6)         1 (1.1)           Diagnosis on admission         Stroke         17 (18.9)         24 (26.7)           Otthopaedics         42 (46.7)         25 (27.8)           Neurological         14 (15.6)         14 (15.6)           Amputation         8 (8.9)         3 (3.3)           Musculoskeletal         2 (2.2)         4 (4.4)           Others         7 (7.8)         29 (22.2)           Comorbidities         Cardiovascular         33 (36.7)         44 (48.9)           Pulmonary         17 (18.9)         16 (17.8)           Stroke         16 (17.8)         29 (22.2)           Comorbidities	Education		
Religion (Christian)       4 (4.4)       4 (4.4)         Interpreter required       16 (17.8)       13 (15.5)         Employment       Employed       18 (20.0)       11 (12.2)         Unemployed       29 (32.2)       29 (32.2)         Retired       43 (47.8)       50 (55.6)         Cognition       Intact       75 (83.3)       85 (94.4)         Mild impairment       10 (11.1)       4 (4.4)         Moderate impairment       5 (5.6)       1 (1.1)         Diagnosis on admission       Stroke       17 (18.9)       24 (26.7)         Orthopaedics       42 (46.7)       25 (27.8)         Neurological       14 (15.6)       14 (15.6)         Amputation       8 (8.9)       3 (3.3)         Musculoskeletal       2 (2.2)       4 (4.4)         Others       7 (7.8)       29 (22.2)         Comorbidities       Cardiovascular       33 (36.7)       44 (48.9)         Pulmonary       17 (18.9)       16 (17.8)         Stroke       16 (17.8)       29 (32.2)         Neurological disorders       24 (26.7)       15 (16.7)         Renal       9 (10)       10 (11.1)         Diabetes       19 (21.1)       31 (34.3)	Secondary/tertiary	86 (95.6)	87 (96.7)
Interpreter required       16 (17.8)       13 (15.5)         Employment       Employed       18 (20.0)       11 (12.2)         Unemployed       29 (32.2)       29 (32.2)         Retired       43 (47.8)       50 (55.6)         Cognition       Intact       75 (83.3)       85 (94.4)         Mild impairment       10 (11.1)       4 (4.4)         Moderate impairment       5 (5.6)       1 (1.1)         Diagnosis on admission       Stroke       17 (18.9)       24 (26.7)         Orthopaedics       42 (46.7)       25 (27.8)         Neurological       14 (15.6)       14 (15.6)         Amputation       8 (8.9)       3 (3.3)         Musculoskeletal       2 (2.2)       4 (4.4)         Others       7 (7.8)       29 (22.2)         Comorbidities       Cardiovascular       33 (36.7)       44 (48.9)         Pulmonary       17 (18.9)       16 (17.8)         Stroke       16 (17.8)       29 (32.2)         Neurological disorders       24 (26.7)       15 (16.7)         Renal       9 (10)       10 (11.1)         Diabetes       19 (21.1)       31 (34.3)         Hypertension       41 (45.6)       51 (56.7)	Postgraduate	4 (4.4)	3 (3.3)
Employment         Employed         18 (20.0)         11 (12.2)           Unemployed         29 (32.2)         29 (32.2)           Retired         43 (47.8)         50 (55.6)           Cognition         Intact         75 (83.3)         85 (94.4)           Mild impairment         10 (11.1)         4 (4.4)           Moderate impairment         5 (5.6)         1 (1.1)           Diagnosis on admission         Stroke         17 (18.9)         24 (26.7)           Orthopaedics         42 (46.7)         25 (27.8)           Neurological         14 (15.6)         14 (15.6)           Amputation         8 (8.9)         3 (3.3)           Musculoskeletal         2 (2.2)         4 (4.4)           Others         7 (7.8)         29 (22.2)           Comorbidities         Cardiovascular         33 (36.7)         44 (48.9)           Pulmonary         17 (18.9)         16 (17.8)         Stroke           Stroke         16 (17.8)         29 (32.2)         Neurological disorders         24 (26.7)         15 (16.7)           Renal         9 (10)         10 (11.1)         11 (34.3)         Hypertension         41 (45.6)         51 (56.7)           Depression         25 (27.8)         18 (20.0)	Religion (Christian)	4 (4.4)	4 (4.4)
Employed         18 (20.0)         11 (12.2)           Unemployed         29 (32.2)         29 (32.2)           Retired         43 (47.8)         50 (55.6)           Cognition         Intact         75 (83.3)         85 (94.4)           Mild impairment         10 (11.1)         4 (4.4)           Moderate impairment         50.6)         11.11           Diagnosis on admission         Stroke         17 (18.9)         24 (26.7)           Orthopaedics         42 (46.7)         25 (27.8)           Neurological         14 (15.6)         14 (15.6)           Amputation         8 (8.9)         3 (3.3)           Musculoskeletal         2 (2.2)         4 (4.4)           Others         7 (7.8)         29 (22.2)           Comorbidities         Z         29 (32.2)           Cancer         17 (18.9)         16 (17.8)           Stroke         16 (17.8)         29 (32.2)           Neurological disorders         24 (26.7)         15 (16.7)           Renal         9 (10)         10 (11.1)           Diabetes         19 (21.1)         31 (34.3)           Hypertension         41 (45.6)         51 (56.7)           Depression         25 (27.8)         18 (2	Interpreter required	16 (17.8)	13 (15.5)
Unemployed         29 (32.2)         29 (32.2)           Retired         43 (47.8)         50 (55.6)           Cognition         Intact         75 (83.3)         85 (94.4)           Mild impairment         10 (11.1)         4 (4.4)           Moderate impairment         5 (5.6)         1 (1.1)           Diagnosis on admission         Stroke         17 (18.9)         24 (26.7)           Orthopaedics         42 (46.7)         25 (27.8)         Neurological           Musculoskeletal         2 (2.2)         4 (4.4)           Others         7 (7.8)         29 (22.2)           Comorbidities         20 (22.2)         Comorbidities           Cardiovascular         33 (36.7)         44 (48.9)           Pulmonary         17 (18.9)         21 (23.3)           Cancer         17 (18.9)         16 (17.8)           Stroke         16 (17.8)         29 (32.2)           Neurological disorders         24 (26.7)         15 (16.7)           Renal         9 (10)         10 (11.1)           Diabetes         19 (21.1)         31 (34.3)           Hypertension         41 (45.6)         51 (56.7)           Depression         25 (27.8)         18 (20.0)           Anxiety	Employment		
Retired         43 (47.8)         50 (55.6)           Cognition         Intact         75 (83.3)         85 (94.4)           Mild impairment         10 (11.1)         4 (4.4)           Moderate impairment         5 (5.6)         1 (1.1)           Diagnosis on admission         Stroke         17 (18.9)         24 (26.7)           Orthopaedics         42 (46.7)         25 (27.8)         Neurological           Amputation         8 (8.9)         3 (3.3)         Musculoskeletal         2 (2.2)         4 (4.4)           Others         7 (7.8)         29 (22.2)         Comorbidities         20 (22.2)           Cardiovascular         33 (36.7)         44 (48.9)         Pulmonary         17 (18.9)         21 (23.3)           Cancer         17 (18.9)         16 (17.8)         29 (32.2)         Neurological disorders         24 (26.7)         15 (16.7)           Renal         9 (10.0)         10 (11.1)         10 (11.1)         10 (11.1)         10 (11.1)           Diabetes         19 (21.1)         31 (34.3)         Hypertension         41 (45.6)         51 (56.7)           Depression         25 (27.8)         18 (20.0)         Anxiety         10 (11.1)         14 (15.6)           Substance use         14 (15.6)	Employed	18 (20.0)	11 (12.2)
Cognition         Intact         75 (83.3)         85 (94.4)           Mild impairment         10 (11.1)         4 (4.4)           Moderate impairment         5 (5.6)         1 (1.1)           Diagnosis on admission         5         5.6)         1 (1.1)           Diagnosis on admission         5         26 (2.7)         0           Orthopaedics         42 (46.7)         25 (27.8)         14 (15.6)           Amputation         8 (8.9)         3 (3.3)         Musculoskeletal         2 (2.2)         4 (4.4)           Others         7 (7.8)         29 (22.2)         Comorbidities         20 (22.2)           Cardiovascular         33 (36.7)         44 (48.9)         Pulmonary         17 (18.9)         21 (23.3)           Cancer         17 (18.9)         16 (17.8)         29 (22.2)         Neurological disorders         24 (26.7)         15 (16.7)           Renal         9 (10)         10 (11.1)         10 (11.1)         10 (11.1)         10 (11.1)           Diabetes <td< td=""><td>Unemployed</td><td>29 (32.2)</td><td>29 (32.2)</td></td<>	Unemployed	29 (32.2)	29 (32.2)
Intact         75 (83.3)         85 (94.4)           Mild impairment         10 (11.1)         4 (4.4)           Moderate impairment         5 (5.6)         1 (1.1)           Diagnosis on admission         5         1 (1.1)           Stroke         17 (18.9)         24 (26.7)           Orthopaedics         42 (46.7)         25 (27.8)           Neurological         14 (15.6)         14 (15.6)           Amputation         8 (8.9)         3 (3.3)           Musculoskeletal         2 (2.2)         4 (4.4)           Others         7 (7.8)         29 (22.2)           Comorbidities         2         2.2.2)           Cardiovascular         33 (36.7)         44 (48.9)           Pulmonary         17 (18.9)         11 (23.3)           Cancer         17 (18.9)         16 (17.8)           Stroke         16 (17.8)         29 (22.2)           Neurological disorders         24 (26.7)         15 (16.7)           Renal         9 (10.0)         10 (11.1)           Diabetes         19 (21.1)         31 (34.3)           Hypertension         41 (45.6)         51 (56.7)           Depression         25 (27.8)         18 (20.0)           Anxiety	Retired	43 (47.8)	50 (55.6)
Mild impairment       10 (11.1)       4 (4.4)         Moderate impairment       5 (5.6)       1 (1.1)         Diagnosis on admission       5       1 (1.1)         Diagnosis on admission       5       24 (26.7)         Stroke       17 (18.9)       24 (26.7)         Othopaedics       42 (46.7)       25 (27.8)         Neurological       14 (15.6)       14 (15.6)         Amputation       8 (8.9)       3 (3.3)         Musculoskeletal       2 (2.2)       4 (4.4)         Others       7 (7.8)       29 (22.2)         Comorbidities       2       2.2.2)         Cardiovascular       33 (36.7)       44 (48.9)         Pulmonary       17 (18.9)       16 (17.8)         Stroke       16 (17.8)       29 (22.2)         Cancer       17 (18.9)       16 (17.8)         Stroke       16 (17.8)       29 (32.2)         Neurological disorders       24 (26.7)       15 (16.7)         Renal       9 (10.0)       10 (11.1)         Diabetes       19 (21.1)       31 (34.3)         Hypertension       41 (45.6)       51 (56.7)         Depression       25 (27.8)       18 (20.0)         Anxiety       10 (	Cognition		
Moderate impairment         5 (5.6)         1 (1.1)           Diagnosis on admission         J         J         J           Stroke         17 (18.9)         24 (26.7)         Orthopaedics         42 (46.7)         25 (27.8)           Orthopaedics         42 (46.7)         25 (27.8)         J         <	Intact	75 (83.3)	85 (94.4)
Diagnosis on admission           Stroke         17 (18.9)         24 (26.7)           Orthopaedics         42 (46.7)         25 (27.8)           Neurological         14 (15.6)         14 (15.6)           Amputation         8 (8.9)         3 (3.3)           Musculoskeletal         2 (2.2)         4 (4.4)           Others         7 (7.8)         29 (22.2)           Comorbidities         Cardiovascular         33 (36.7)         44 (48.9)           Pulmonary         17 (18.9)         21 (23.3)         Cancer           Carcer         17 (18.9)         16 (17.8)         Stroke           Stroke         16 (17.8)         29 (32.2)         Neurological disorders         24 (26.7)         15 (16.7)           Renal         9 (10)         10 (11.1)         10 (11.1)         Diabetes         19 (21.1)         31 (34.3)           Hypertension         41 (45.6)         51 (56.7)         Depression         25 (27.8)         18 (20.0)           Anxiety         10 (11.1)         14 (15.6)         Substance use         14 (15.6)         Stroke         15 (16.7)         17 (18.9)         Other (arthritis, osteoporosis, etc.)         65 (72.2)           ACP components         XCP disccussions         9 (10.0)         21	Mild impairment	10 (11.1)	4 (4.4)
Stroke         17 (18.9)         24 (26.7)           Orthopaedics         42 (46.7)         25 (27.8)           Neurological         14 (15.6)         14 (15.6)           Amputation         8 (8.9)         3 (3.3)           Musculoskeletal         2 (2.2)         4 (4.4)           Others         7 (7.8)         29 (22.2)           Comorbidities         2         2000000000000000000000000000000000000	Moderate impairment	5 (5.6)	1 (1.1)
Orthopaedics         42 (46.7)         25 (27.8)           Neurological         14 (15.6)         14 (15.6)           Amputation         8 (8.9)         3 (3.3)           Musculoskeletal         2 (2.2)         4 (4.4)           Others         7 (7.8)         29 (22.2)           Comorbidities	Diagnosis on admission		
Neurological         14 (15.6)         14 (15.6)           Amputation         8 (8.9)         3 (3.3)           Musculoskeletal         2 (2.2)         4 (4.4)           Others         7 (7.8)         29 (22.2)           Comorbidities	Stroke	17 (18.9)	24 (26.7)
Amputation         8 (8.9)         3 (3.3)           Musculoskeletal         2 (2.2)         4 (4.4)           Others         7 (7.8)         29 (22.2)           Comorbidities         2         2           Cardiovascular         33 (36.7)         44 (48.9)           Pulmonary         17 (18.9)         21 (23.3)           Cancer         17 (18.9)         16 (17.8)           Stroke         16 (17.8)         29 (32.2)           Neurological disorders         24 (26.7)         15 (16.7)           Renal         9 (10)         10 (11.1)           Diabetes         19 (21.1)         31 (34.3)           Hypertension         41 (45.6)         51 (56.7)           Depression         25 (27.8)         18 (20.0)           Anxiety         10 (11.1)         14 (15.6)           Substance use         14 (15.6)         14 (15.6)           Smoker         15 (16.7)         17 (18.9)           Other (arthritis, osteoporosis, etc.)         71 (78.9)         65 (72.2)           ACP discussions         9 (10.0)         21 (23.3)           MEPOA nomination         7 (7.8)         3 (3.3)	Orthopaedics	42 (46.7)	25 (27.8)
Musculoskeletal         2 (2.2)         4 (4.4)           Others         7 (7.8)         29 (22.2)           Comorbidities         2         2           Cardiovascular         33 (36.7)         44 (48.9)           Pulmonary         17 (18.9)         21 (23.3)           Cancer         17 (18.9)         16 (17.8)           Stroke         16 (17.8)         29 (32.2)           Neurological disorders         24 (26.7)         15 (16.7)           Renal         9 (10)         10 (11.1)           Diabetes         19 (21.1)         31 (34.3)           Hypertension         41 (45.6)         51 (56.7)           Depression         25 (27.8)         18 (20.0)           Anxiety         10 (11.1)         14 (15.6)           Substance use         14 (15.6)         14 (15.6)           Smoker         15 (16.7)         17 (18.9)           Other (arthritis, osteoporosis, etc.)         71 (78.9)         65 (72.2)           ACP components         4CP discussions         9 (10.0)         21 (23.3)           MEPOA nomination         7 (7.8)         3 (3.3)	Neurological	14 (15.6)	14 (15.6)
Others         7 (7.8)         29 (22.2)           Comorbidities         -         -           Cardiovascular         33 (36.7)         44 (48.9)           Pulmonary         17 (18.9)         21 (23.3)           Cancer         17 (18.9)         16 (17.8)           Stroke         16 (17.8)         29 (32.2)           Neurological disorders         24 (26.7)         15 (16.7)           Renal         9 (10)         10 (11.1)           Diabetes         19 (21.1)         31 (34.3)           Hypertension         41 (45.6)         51 (56.7)           Depression         25 (27.8)         18 (20.0)           Anxiety         10 (11.1)         14 (15.6)           Substance use         14 (15.6)         14 (15.6)           Smoker         15 (16.7)         17 (18.9)           Other (arthritis, osteoporosis, etc.)         65 (72.2)           ACP components         -         -           MEPOA nomination         7 (7.8)         3 (3.3)	Amputation	8 (8.9)	3 (3.3)
Comorbidities           Cardiovascular         33 (36.7)         44 (48.9)           Pulmonary         17 (18.9)         21 (23.3)           Cancer         17 (18.9)         16 (17.8)           Stroke         16 (17.8)         29 (32.2)           Neurological disorders         24 (26.7)         15 (16.7)           Renal         9 (10)         10 (11.1)           Diabetes         19 (21.1)         31 (34.3)           Hypertension         41 (45.6)         51 (56.7)           Depression         25 (27.8)         18 (20.0)           Anxiety         10 (11.1)         14 (15.6)           Substance use         14 (15.6)         14 (15.6)           Smoker         15 (16.7)         17 (18.9)           Other (arthritis, osteoporosis, etc.)         71 (78.9)         65 (72.2)           ACP components         40.00         21 (23.3)           MEPOA nomination         7 (7.8)         3 (3.3)	Musculoskeletal	2 (2.2)	4 (4.4)
Cardiovascular       33 (36.7)       44 (48.9)         Pulmonary       17 (18.9)       21 (23.3)         Cancer       17 (18.9)       16 (17.8)         Stroke       16 (17.8)       29 (32.2)         Neurological disorders       24 (26.7)       15 (16.7)         Renal       9 (10)       10 (11.1)         Diabetes       19 (21.1)       31 (34.3)         Hypertension       41 (45.6)       51 (56.7)         Depression       25 (27.8)       18 (20.0)         Anxiety       10 (11.1)       14 (15.6)         Substance use       14 (15.6)       14 (15.6)         Smoker       15 (16.7)       17 (18.9)         Other (arthritis, osteoporosis, etc.)       71 (78.9)       65 (72.2)         ACP components       9 (10.0)       21 (23.3)         MEPOA nomination       7 (7.8)       3 (3.3)	Others	7 (7.8)	29 (22.2)
Pulmonary       17 (18.9)       21 (23.3)         Cancer       17 (18.9)       16 (17.8)         Stroke       16 (17.8)       29 (32.2)         Neurological disorders       24 (26.7)       15 (16.7)         Renal       9 (10)       10 (11.1)         Diabetes       19 (21.1)       31 (34.3)         Hypertension       41 (45.6)       51 (56.7)         Depression       25 (27.8)       18 (20.0)         Anxiety       10 (11.1)       14 (15.6)         Substance use       14 (15.6)       14 (15.6)         Smoker       15 (16.7)       17 (18.9)         Other (arthritis, osteoporosis, etc.)       71 (78.9)       65 (72.2)         ACP components       9 (10.0)       21 (23.3)         MEPOA nomination       7 (7.8)       3 (3.3)	Comorbidities		
Cancer       17 (18.9)       16 (17.8)         Stroke       16 (17.8)       29 (32.2)         Neurological disorders       24 (26.7)       15 (16.7)         Renal       9 (10)       10 (11.1)         Diabetes       19 (21.1)       31 (34.3)         Hypertension       41 (45.6)       51 (56.7)         Depression       25 (27.8)       18 (20.0)         Anxiety       10 (11.1)       14 (15.6)         Substance use       14 (15.6)       14 (15.6)         Smoker       15 (16.7)       17 (18.9)         Other (arthritis, osteoporosis, etc.)       71 (78.9)       65 (72.2)         ACP discussions       9 (10.0)       21 (23.3)         MEPOA nomination       7 (7.8)       3 (3.3)	Cardiovascular	33 (36.7)	44 (48.9)
Stroke         16 (17.8)         29 (32.2)           Neurological disorders         24 (26.7)         15 (16.7)           Renal         9 (10)         10 (11.1)           Diabetes         19 (21.1)         31 (34.3)           Hypertension         41 (45.6)         51 (56.7)           Depression         25 (27.8)         18 (20.0)           Anxiety         10 (11.1)         14 (15.6)           Substance use         14 (15.6)         14 (15.6)           Smoker         15 (16.7)         17 (18.9)           Other (arthritis, osteoporosis, etc.)         71 (78.9)         65 (72.2)           ACP components         9 (10.0)         21 (23.3)           MEPOA nomination         7 (7.8)         3 (3.3)	Pulmonary	17 (18.9)	21 (23.3)
Neurological disorders         24 (26.7)         15 (16.7)           Renal         9 (10)         10 (11.1)           Diabetes         19 (21.1)         31 (34.3)           Hypertension         41 (45.6)         51 (56.7)           Depression         25 (27.8)         18 (20.0)           Anxiety         10 (11.1)         14 (15.6)           Substance use         14 (15.6)         14 (15.6)           Smoker         15 (16.7)         17 (18.9)           Other (arthritis, osteoporosis, etc.)         71 (78.9)         65 (72.2)           ACP components         9 (10.0)         21 (23.3)           MEPOA nomination         7 (7.8)         3 (3.3)	Cancer	17 (18.9)	16 (17.8)
Renal         9 (10)         10 (11.1)           Diabetes         19 (21.1)         31 (34.3)           Hypertension         41 (45.6)         51 (56.7)           Depression         25 (27.8)         18 (20.0)           Anxiety         10 (11.1)         14 (15.6)           Substance use         14 (15.6)         14 (15.6)           Smoker         15 (16.7)         17 (18.9)           Other (arthritis, osteoporosis, etc.)         71 (78.9)         65 (72.2)           ACP components         4CP discussions         9 (10.0)         21 (23.3)           MEPOA nomination         7 (7.8)         3 (3.3)	Stroke	16 (17.8)	29 (32.2)
Diabetes         19 (21.1)         31 (34.3)           Hypertension         41 (45.6)         51 (56.7)           Depression         25 (27.8)         18 (20.0)           Anxiety         10 (11.1)         14 (15.6)           Substance use         14 (15.6)         14 (15.6)           Smoker         15 (16.7)         17 (18.9)           Other (arthritis, osteoporosis, etc.)         71 (78.9)         65 (72.2)           ACP components         4CP discussions         9 (10.0)         21 (23.3)           MEPOA nomination         7 (7.8)         3 (3.3)	Neurological disorders	24 (26.7)	15 (16.7)
Hypertension         41 (45.6)         51 (56.7)           Depression         25 (27.8)         18 (20.0)           Anxiety         10 (11.1)         14 (15.6)           Substance use         14 (15.6)         14 (15.6)           Substance use         14 (15.6)         14 (15.6)           Other (arthritis, osteoporosis, etc.)         71 (78.9)         65 (72.2)           ACP components         40.00         21 (23.3)           MEPOA nomination         7 (7.8)         3 (3.3)	Renal	9 (10)	10 (11.1)
Depression         25 (27.8)         18 (20.0)           Anxiety         10 (11.1)         14 (15.6)           Substance use         14 (15.6)         14 (15.6)           Smoker         15 (16.7)         17 (18.9)           Other (arthritis, osteoporosis, etc.)         71 (78.9)         65 (72.2)           ACP components         4CP discussions         9 (10.0)         21 (23.3)           MEPOA nomination         7 (7.8)         3 (3.3)	Diabetes	19 (21.1)	31 (34.3)
Anxiety       10 (11.1)       14 (15.6)         Substance use       14 (15.6)       14 (15.6)         Smoker       15 (16.7)       17 (18.9)         Other (arthritis, osteoporosis, etc.)       71 (78.9)       65 (72.2)         ACP components       4CP discussions       9 (10.0)       21 (23.3)         MEPOA nomination       7 (7.8)       3 (3.3)	Hypertension	41 (45.6)	51 (56.7)
Substance use         14 (15.6)         14 (15.6)           Smoker         15 (16.7)         17 (18.9)           Other (arthritis, osteoporosis, etc.)         71 (78.9)         65 (72.2)           ACP components         4CP discussions         9 (10.0)         21 (23.3)           MEPOA nomination         7 (7.8)         3 (3.3)	Depression	25 (27.8)	18 (20.0)
Smoker         15 (16.7)         17 (18.9)           Other (arthritis, osteoporosis, etc.)         71 (78.9)         65 (72.2)           ACP components         ACP discussions         9 (10.0)         21 (23.3)           MEPOA nomination         7 (7.8)         3 (3.3)	Anxiety	10 (11.1)	14 (15.6)
Other (arthritis, osteoporosis, etc.)         71 (78.9)         65 (72.2)           ACP components         ACP discussions         9 (10.0)         21 (23.3)           MEPOA nomination         7 (7.8)         3 (3.3)	Substance use	14 (15.6)	14 (15.6)
etc.)         71 (78.9)         65 (72.2)           ACP components         4CP discussions         9 (10.0)         21 (23.3)           MEPOA nomination         7 (7.8)         3 (3.3)	Smoker	15 (16.7)	17 (18.9)
ACP components         9 (10.0)         21 (23.3)           MEPOA nomination         7 (7.8)         3 (3.3)		71 (78 0)	6E (72 2)
ACP discussions         9 (10.0)         21 (23.3)           MEPOA nomination         7 (7.8)         3 (3.3)	•	/1 (/0.9)	05 (72.2)
MEPOA nomination 7 (7.8) 3 (3.3)	•	9 (10.0)	21 (23.3)
		. ,	. ,
		. ,	
SD: standard deviation: ACP: advance care planning: MEPOA: medical endur			

SD: standard deviation; ACP: advance care planning; MEPOA: medical enduring power of attorney; AD: advance directive.

facilitators were analysed qualitatively and findings included:

## 1) Pre-implementation phase

Written survey feedback

*Healthcare provider characteristics.* Twenty-six (n=26, 61.9%) out of 42 rehabilitation staff participated in the pre-implementation written survey, which assessed barriers and facilitators to ACP implementation. There were 8 (30.7%) medical, 13 (50%) nursing and 5 (19.2%) allied health staff. The majority (30.7%, n=8) were in the 30–39 years age group; 80.8% (n=21) were female and 53.8% (n=14) had > 10 years of experience in clinical practice.

Knowledge and use of ACP. Most rehabilitation staff felt that they were "somewhat familiar" with ACP (n=14). Seven (n=7) stated that they had never discussed ACP with their patients, with 10 rarely discussing ACP. Most (n=19) stated that they had not received formal education or training regarding ACP. Rehabilitation staff most commonly discussed ACP when prompted by patient/family (n=12) and/ or after a change in health status (n=11).

Barriers to effective ACP discussions. The most prevalent provider-level barriers included the lack of a staff education programme (n=16), not having the knowledge or skills the discussion (n=12), insufficient experience in facilitating discussions (n=12) and difficulty defining the right moment for ACP discussions (n=11) (Table III). The most prevalent system-level barriers were the lack of ACP awareness campaigns in the organization (n=12) and limited electronic health record capability to track conversations (n=8).

Facilitators to effective ACP discussions. The most common facilitators include the increasing understanding of ACP discussions (n=17) and ability of ACP to improve clinical care for patients (n=14) (Table III).

Focus groups

Of the 26 people who responded to the ACP survey tool, 5 were randomly selected to represent all craft groups within rehabilitation (medical, nursing, allied health). Qualitative analysis of focus group findings indicated that barriers to ACP also included: rehabilitation staff often feeling that patients who have temporary conditions, or young age as not being applicable for initiation of ACP discussions. Some also felt that the rehabilitation setting may not be seen as an appropriate environment to discuss ACP, given that the aim of rehabilitation involves restoration of function and community reintegration rather than discussing EOL issues. In addition, the rehabilitation specialty is often not seen by other specialties and organizational administration as involved in ACP discussions.

## 2) Post implementation

• Focus groups

Qualitative analysis of focus group findings demonstrated ongoing staff barriers to ACP post-implementation. These included limited time and resources, as well as lack of communication skills to perform ACP discussions with patients. Despite these, they continued to feel positive regarding its importance and are motivated to overcome barriers to ACP implementation. They have found that provision of ACP documents improves accessibility and improved the effectiveness of documentation of ACP discussions. **Table III.** Pre-implementation perceived advance care planning (ACP) barriers and facilitators (n = 26)

System	Barriers to ACP	n (%)
Provider-level	Lack of staff ACP education/training programme	16 (61.5)
	Insufficient knowledge/skills to have the discussion	12 (46.2)
	Insufficient experience in discussing ACP	12 (46.2)
	Difficulty defining the right moment	11 (42.3)
	Discomfort in initiating the discussion	10 (38.5)
	Do not remember to discuss ACP	9 (34.6)
Systemic-level	Lack of ACP awareness campaigns in the organization	12 (46.2)
	Lack of electronic health record capability to track ACP conversations	8 (30.8)
	Lack of facilities (e.g. quiet rooms, privacy) to facilitate ACP discussions	8 (30.8)
	Lack of access to ACP resources (printed and digital documents, videos etc.)	8 (30.8)
	Inadequate alert/reminder system	7 (26.9)
	Lack of documentation/ACP policies in the organization	7 (26.9)
	Facilitators to ACP	
	Increasing understanding of ACP discussions	17 (65.4)
	Ability of ACP to improve clinical care for patients	14 (53.8)
	Presence of educational initiatives enabling skills development	12 (46.2)
	ACP is considered as part of the role of my job	8 (30.8)
	Positive experiences with EOL conversations in the past	7 (26.9)
	Accumulated skills to be able to perform ACP discussions and facilitate conversations	6 (23.1)

ACP: advance care planning; EOL: end-of-life.

# *Evaluation of ACP programme using RE-AIM framework*

The RE-AIM framework was used to evaluate the ACP programme. The particular elements considered and used for analysis are summarized in Table IV, and the impact of programme discussed.

#### DISCUSSION

To our knowledge, this is the first process evaluation study of an ACP programme established in a rehabilitation setting to inform on its effectiveness, delivery and quality. Consistent with previous ACP studies, the study findings demonstrate the ongoing low uptake of ACP in rehabilitation settings in Australia, including the occurrence of ACP conversations and its components, especially amongst those with chronic illnesses, such as stroke, neurological conditions, cancer, chronic respiratory and cardiovascular disease (4, 11, 12, 20). To address this evidence-practice gap, we implemented a structured ACP programme in a rehabilitation setting in a tertiary hospital in Australia, and used the RE-AIM implementation framework as a process evaluation tool to identify mitigable barriers and implement strategies with contextual adaptations that can be easily adopted in real-life clinical practice (14). The post-implementation findings of this study

Journal of Rehabilitation Medicine

Table IV. Evaluation of advance care planning (ACP) programme using Reach, Effectiveness, Adoption, Implementation, Maintenance (DE ATM) f 

RE-AIM domains	Key factors	Pre-implementation	Implementation	Post-implementation	Impact of programme
Reach	Target population willing to participate in programme	Target population included inpatient rehabilitation patients with chronic life-limiting illnesses and/ or those with multiple comorbidities. Target population also included rehabilitation staff (medical, nursing and allied health)	Rehabilitation staff incorporated ACP discussions into routine clinical care and participated in implementing clinical process changes (e.g. use of ACP discussion forms, provision of patient information brochures)	Similar recruitment of inpatient rehabilitation patients to pre- implementation cohort	Good reach of interventions to eligible populations based on participation rates
Effectiveness	Impact of intervention on important outcomes	- ,		Increase in ACP conversations performed in post-implementation cohort (n=21, 23.3%) No effects on MEPOA and AD completion documentation rates	Good impact on initiation and facilitation of ACP discussions Factors contributing to insignificant increase in MEPOA nomination and AD completion rates possibly related to limiter follow-up period towards these outcomes. Further longer term studies required to evaluate these outcomes, including patient QoL.
Adoption	Adoption of intervention by staff and services	Exploration of staff barriers and facilitators to implementing ACP using feedback survey tool, and focus groups	Initiation of ACP conversations and information delivery to patients by staff	ACP information was well received by patients, with no unwanted effects including psychological harm/challenges recorded in medical record audit Staff felt positive regarding ACP implementation and motivated to overcoming barriers, despite increased resources and time required	Overall positive attitude of rehabilitation staff towards intervention strategies suggest good adoption, consistent with post-implementation results of study
		Settings			-
		Widespread implementation of ACP is beyond scope of study and limited to inpatient setting; not performed in ambulatory or community care settings.			
Implementation	Extent to which programme is delivered as intended in real world settings rather than clinically controlled research settings	Cost	Intervention amount Delivery of ACP education sessions to rehabilitation staff in separate sessions to each discipline (medical, nursing and allied health) and also in separate multidisciplinary forum Weekly multidisciplinary meeting goal checklists incorporating ACP Provision ACP information brochures to patients on admission to the ward Provision of ACP documents on ward for easy accessibility and embedding ACP discussion forms into patient folders	Staff fidelity Variable consistency of f ACP content delivery and duration of discussions due to individualized ACP conversations for target population Staff fidelity was gauged from contents of ACP discussions recorded in ACP discussion forms and filed in medical records.	Positive short term impacts of ACP programme on outcomes measured, demonstrating feasibility of ACP programme i real world clinical practice. Further larger and longer term follow-up studies are required to demonstrate the true effect of these.
			ost analysis was not within the scope of this study. However, the direct costs of		- Cost-effectiveness analysis
		providing rehabilitation programs are calculated based on a rate of AUD250 per 1-h session. This covers rehabilitation staff time, administrative costs (e.g. stationary, computer costs), utilities (e.g. lighting, electricity), building maintenance and cleaning. Allocated resources No additional resources were allocated as the study involved current rehabilitation staff employees who incorporated ACP into routine care.			would be important if widespread implementation o ACP was to be considered
Maintenance	Long-term effects of intervention on individual and settings			Incorporation of ACP into routine practice undertaken by rehabilitation staff	Long-term benefits for patient can be assessed in future larger and longer term follow- up studies including MEPOA nomination, AD completion, impact on EOL decision-makin quality of ACP conversations, patient and caregiver QoL, longer term quality of care, re-hospitalization rate and mortality outcomes. Analysis of cost-benefit is required to assess long-term benefits of ACP in rehabilitation

ACP: advance care planning; MEPOA: medical enduring power of attorney; AD: advance directive; QoL: quality of life.

JRIV

highlighted the feasibility and positive outcomes of the programme, with increased ACP conversations between rehabilitation staff and patients.

With the increasing emphasis on the integration of EOL skills amongst healthcare providers in Australia, significant cultural and organizational changes are necessary to deliver safe and high-quality EOL care (21). Continuity care providers, such as rehabilitation staff, are uniquely positioned to provide ACP counselling and resources to their patients, as ACP is a longitudinal task optimally facilitated by the provider who is familiar with their condition (10). Rehabilitation is known to have an important role in the treatment and management of most advanced chronic illnesses, such as amyotrophic lateral sclerosis, multiple sclerosis, spinal cord injury, and end-stage lung and heart disease (10). The multidisciplinary team approach allows staff to contribute information about treatments and interventions based on their area of expertise, break the task down into manageable components, assist with problem-solving complex issues using appropriate communication approaches, and use their areas of competency in setting goals of care (2). Often, the unique and uncertain disease trajectories of chronic illnesses, coupled with the high burden of chronically debilitating symptoms and other comorbidities can affect survival, making EOL discussions important as early on as possible. The rehabilitation team is able to help facilitate discussions involving the use of mechanical ventilation, antibiotics, artificial nutrition, and hydration, with the aim of maintaining and/ or improving QoL for patients.

The study findings identified multiple staff and systemic barriers in rehabilitation to discussing ACP including limited awareness of ACP and education programmes, as well as the role of rehabilitation in ACP. Despite this, facilitators indicate that rehabilitation staff do perceive its usefulness and are aware of its benefits. These factors encourage continuing and further professional development opportunities for rehabilitation staff in improving ACP knowledge and communication skills, upskilling in best practice EOL care management, with better access to education and training programmes, ACP leadership support for staff, and provision of ACP guidelines and resources. Other recommended rehabilitation service goals include support of governance and administrative initiatives surrounding ACP, mortality and morbidity audits, and quality improvement processes (21). The accessibility of ACP plans is also important and forms a core component of a long-term systemic approach, including ensuring core documentation for transfer of care, system of alerts and triggers to indicate that a person has an ACP, and ease of its accessibility across health services.

It has been shown that patients with chronic illnesses desire communication about ACP and education about topics such as diagnosis and disease process, prognosis, surrogate decision-making, life-sustaining treatments and AD (22, 23). Given the significant number of patients from different cultural and linguistic backgrounds identified in this study, the findings also highlighted that clinicians need to be open to understanding and learning different attitudes and cultural practices in discussing ACP. Education should include specific training for communicating with patients from culturally and linguistically diverse communities and the consideration of their cultural values, beliefs and practices. The use of accredited interpreters is also important to ensure that appropriate and culturally sensitive information is offered and provided.

#### Study limitations

This study has several limitations. Though the RE-AIM framework is a comprehensive tool for examining programme delivery and effectiveness, it is possible that some implementation processes may affect more than 1 of the 5 domains. For example, rehabilitation staff expertise, beliefs and attitudes may influence effectiveness, adoption and implementation. Some elements of RE-AIM, such as maintenance, were not addressed to their full extent, as implementation of the intervention was not followed up in the long-term to assess other outcomes. It did, however, generate preliminary data to support a future, large-scale intervention trial that can further tailor the ACP interventions, and assess intervention effects on healthcare received and long-term patient outcomes. This study was also not a randomized controlled trial and, hence, did not have any comparator. Potential for both recall bias and respondents' tendency to provide socially desirable answers cannot be ruled out. However, this was minimized by making survey responses anonymous. Furthermore, this study was conducted in a single rehabilitation inpatient setting, which may limit its generalizability to other settings. However, the use of a formal evaluation framework and well-defined statements of implementation research questions and presentation of clear results and the nature of the programme activities utilized could be feasibly replicated at other institutions.

## Conclusion

This pragmatic quality improvement study established the importance of process evaluation when evaluating complex interventions, such as ACP. The findings provided greater explanatory power for the outcomes of an ACP programme and identified process factors

requiring further research. It also demonstrated that an ACP education intervention is a feasible way to improve ACP discussions and documentation, and identified key practice-based improvement strategies. The ACP programme aimed to empower rehabilitation staff to drive system changes and build consensus in this complex area, with support from clinical leads. Further robust and larger studies are needed to evaluate the efficacy of the ACP intervention for longer term patient outcomes, and alignment of treatment with the best interests of patients to inform future policies and practice.

The authors have no conflicts of interest to declare.

## **REFERENCES**

- 1. Australian Institute of Health and Welfare (AIHW). Leading causes of death. 2013 [cited 2018 Jan 12]. Available from: http: //www.aihw.gov.au/deaths/leading-causes-of-death.
- Victoria State Government. Initiating Advance Care Planning. 2017 [cited 2017 Dec 12] Available from: https: // www2.health.vic.gov.au/hospitals-and-health-services/ patient-care/end-of-life-care/advance-care-planning/ acp-initiating.
- Detering KM, Hancock AD, Reade MC, Silvester W. The impact of advance care planning on end of life care in elderly patients: randomized controlled trial. BMJ 2010; 340: c1345.
- Song K, Amatya B, Drummond K, Khan F. Advance care planning in brain tumour survivors: a prospective study. Int J Cancer Res Ther 2017; 2: 1–10.
- Song K, Amatya B, Khan F. Advance care planning in patients with primary malignant brain tumors: a systematic review. Frontiers Oncol 2016; 6: 223.
- A National Framework for Advance Care Directives. The Clinical, Technical and Ethical Principal Committee of the Australian Health Ministers' Advisory Council. 2011 [cited 2018 Jan 12]. Available from: http://www.coaghealthcouncil. gov.au/Portals/0/A%20National%20Framework%20for%20 Advance%20Care%20Directives\_September%202011.pdf.
- Ramsaroop SD, Reid MC, Adelman RD. Completing advance directive in the primary care setting: what do we need for success. J Am Geriatr Soc 2007; 55: 277–283.
- Gadoud A, Jenkins SM, Hogg KJ. Palliative care for people with heart failure: summary of current evidence and future direction. Palliat Med 2013; 27: 822–828.

- Hardin KA, Meyers F, Louie S. Integrating palliative care in severe chronic obstructive lung disease. COPD 2008; 5: 207–220.
- Turner-Stokes L, Sykes N, Silber E, Khatri A, Sutton L, Young E. From diagnosis to death: exploring the interface between neurology, rehabilitation and palliative care in the management of people with long term neurological conditions. Clin Med 2007; 7: 129–136.
- Heffner JE, Barbieri C. Effects of advance care education in cardiovascular rehabilitation programs: a prospective randomized study. J Cardiopulm Rehabil 2001; 21: 387–391.
- Heffner JE, Fahy B, Hilling L, Barbieri C. Outcomes of advance directive education of pulmonary rehabilitation patients. Am J Resp Crit Care Med 1997; 155: 1055–1059.
- 13. Sanchez A, Silvestre C, Campo N, Gradnes G. Type-2 diabetes primary prevention program implemented in routine primary care: a process evaluation study. Trials 2016; 17: 254.
- 14. Estabrooks P. Reach effectiveness adoption implementation maintenance. 2016 [cited 2017 Nov 22]. Available from: http://re-aim.org/.
- Medical Research Council. Developing and evaluating complex interventions: new guidance. 2008 [cited 2018 Jan 12]. Available from: http: //www.mrc.ac.uk/documents/ pdf/complex-interventions-guidance/.
- Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Am J Public Health 1999; 89: 1322–1327.
- 17. Given LM. The Sage encyclopedia of qualitative research methods. Los Angeles: Sage Publications; 2008.
- National Health and Medical Research Council. National Statement on Ethical Conduct in Human Research (Australian Government); 2007 [updated 2015 May; cited 2018 Jan 12]. Available from: http://www.nhmrc.gov.au/book/ chapter-3-1-qualitative-methods.
- Community interventions for health. An Oxford health alliance programme. 2016 [cited 2017 Dec 4]. Available from: http: //www.oxha.org/cih\_manual/index.php/ process-evaluation.
- Patel K, Janssen DJ, Curtis JR. Advance care planning in COPD. Respirology 2012; 17: 72–78.
- 21. Australian Commission on Safety & Quality in Health Care: National safety & quality health service standards. Sydney: ACSQHC; 2011.
- Heffner JE, Fahy B, Hilling L, Barbieri C. Attitudes regarding advance directives among patients in pulmonary rehabilitation. Am J Respir Crit Care Med 1996; 154: 1735–1740.
- 23. Curtis JR, Wenrich MD, Carline JD, Shannon SE, Ambrozy DM, Ramsey PG. Patients' perspectives on physician skill in end-of-life care: differences between patients with COPD, cancer and AIDS. Chest 2002; 122: 356–362.